Introduction:

About 20 to 40% of ischaemic stroke causes are cryptogenic. Embolic stroke of undetermined source (ESUS) is a subtype of cryptogenic stroke which is diagnosed based on specific criteria. Even though patent foramen ovale (PFO) is linked with the risk of stroke, it is found in about 25% of the general population, so it might be an innocent bystander. The best way to treat ESUS patients with PFO is still up for discussion.

Materials and methods:

Therefore, based on current evidence and expert opinion, Malaysian expert panels from various disciplines have gathered to discuss the management of ESUS patients with PFO. This consensus sought to educate Malaysian healthcare professionals to diagnose and manage PFO in ESUS patients based on local resources and facilities.

Results:

Based on consensus, the Malaysian expert recommended PFO closure for embolic stroke patients who were younger than 60, had high RoPE scores and did not require long-term anticoagulation. However, the decision should be made after other mechanisms of stroke have been ruled out via thorough investigation and multidisciplinary evaluation. The PFO screening should be made using readily available imaging modalities, ideally contrasttransthoracic echocardiogram (c-TTE) or contrasttranscranial Doppler (c-TCD). The contrast-transesophageal echocardiogram (c-TEE) should be used for the confirmation of PFO diagnosis. The experts advised closing PFO as early as possible because there is limited evidence for late closure. For the post-closure follow-up management, dual antiplatelet therapy (DAPT) for one to three months, followed by single antiplatelet therapy (APT) for six months, is advised. Nonetheless, with joint care from a cardiologist and a neurologist, the multidisciplinary team will decide on the continuation of therapy.

1. Institute for Health Metrics and Evaluation. Malaysia 2021 [cited Jun 2022]. Available from: https://www.healthdata.org/malaysia.
2. Cheah WK, Hor CP, Zariah AA, Looi I. A Review of Stroke Research in Malaysia from 2000 - 2014. Med J Malaysia 2016; 71(Suppl 1): 58-69.
3. Institute for Public Health Ministry of Health Malaysia. NHMS Report 2011 Volume III - Healthcare Demand And Out-Of-Pocket Health Expenditure 2012 [cited 2022 Jun]. Available from: https://iku.moh.gov.my/images/IKU/Document/REPORT/NHMS2011-VolumeIII.pdf.
4. Amal NM, Paramesarvathy R, Tee GH, Gurpreet K, Karuthan C. Prevalence of Chronic Illness and Health Seeking Behaviour in Malaysian Population: Results from the Third National Health Morbidity Survey (NHMS III) 2006. Med J Malaysia 2011; 66(1): 36–41.
5. Aziz ZA, Lee YY, Ngah BA, Sidek NN, Looi I, Hanip MR, et al. Acute Stroke Registry Malaysia, 2010-2014: Results from the National Neurology Registry. J Stroke Cerebrovasc Dis 2015; 24(12): 2701–9.
6. Malaysian Society of Neurosciences. Annual Report of the Malaysian Stroke Registry 2009-2016 [cited 2022 Jun]. Available from: https://www.neuro.org.my/assets/guideline/Stroke%20registry%20report%202009-2016.pdf.
7. Nazifah SN, Azmi IK, Hamidon BB, Looi I, Zariah AA, Hanip MR. National Stroke Registry (NSR): Terengganu and Seberang Jaya experience. Med J Malaysia 2012; 67(3): 302–4.
8. Ministry of Health Malaysia. Clinical Practice Guideline: Management of Ischaemic Stroke (3rd Edition) 2020 [cited Jun 2022]. Available from: https://www.moh.gov.my/index.php/pages/view/133.
9. Ntaios G, Tzikas A, Vavouranakis E, Nikas D, Katsimagklis G, Koroboki E, et al. Expert consensus statement for the management of patients with embolic stroke of undetermined source and patent foramen ovale: A clinical guide by the working group for stroke of the Hellenic Society of Cardiology and the Hellenic Stroke Organisation. Hellenic J Cardiol 2020; 61(6): 435–41.
10. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13(4): 429–38.
11. Homma S, Messe SR, Rundek T, Sun YP, Franke J, Davidson K, et al. Patent foramen ovale. Nat Rev Dis Primers 2016; 2: 15086.
12. Ioannidis SG, Mitsias PD. Patent foramen ovale in cryptogenic ischaemic stroke: direct cause, risk factor, or incidental finding? Front Neurol 2020; 11: 567.
13. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368(12): 1092–100.
14. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366(11): 991–9.
15. Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, et al. Cryptogenic stroke and high-risk patent foramen ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol 2018; 71(20): 2335–42.
16. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med 2017; 377(11): 1011–21.
17. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368(12): 1083–91.
18. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377(11): 1022–32.
19. Sondergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377(11): 1033–42.
20. Diener HC, Akagi T, Durongpisitkul K, Thomson VS, Prabhakar AT, Sharpe R, et al. Closure of the patent foramen ovale in patients with embolic stroke of undetermined source: A clinical expert opinion and consensus statement for the Asian-Pacific region. Int J Stroke 2020; 15(9): 937–44.
21. Messe SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology 2020; 94(20): 876–85.
22. Keach JW, Bradley SM, Turakhia MP, Maddox TM. Early detection of occult atrial fibrillation and stroke prevention. Heart 2015; 101(14): 1097–102.
23. Pristipino C, Sievert H, D'Ascenzo F, Louis Mas J, Meier B, Scacciatella P, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J 2019; 40(38): 3182–95.
24. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischaemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52(7): e364-e467.
25. Ibeh C, Elkind MSV. Stroke prevention after cryptogenic stroke. Curr Cardiol Rep 2021; 23(12): 174.
26. Gusdon AM, Farrokh S, Grotta JC. Antithrombotic therapy for stroke patients with cardiovascular disease. Semin Neurol 2021; 41(4): 365–87.
27. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, et al. Detection of atrial fibrillation after ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis. Stroke 2014; 45(2): 520–6.
28. Bhat A, Mahajan V, Chen HHL, Gan GCH, Pontes-Neto OM, Tan TC. Embolic stroke of undetermined source: approaches in risk stratification for cardioembolism. Stroke 2021; 52(12): e820–e36.
29. Tsai LK, Lee IH, Chen YL, Chao TF, Chen YW, Po HL, et al. Diagnosis and Treatment for embolic stroke of undetermined source: Consensus statement from the Taiwan stroke society and Taiwan society of cardiology. J Formos Med Assoc 2021; 120(1 Pt 1): 93–106.
30. Collado FMS, Poulin MF, Murphy JJ, Jneid H, Kavinsky CJ. Patent foramen ovale closure for stroke prevention and other disorders. J Am Heart Assoc 2018; 7(12).
31. Braemswig TB, Usnich T, Scheitz JF, Erdur H, Fiebach JB, Audebert HJ, et al. Early recurrent ischaemic lesions in patients with cryptogenic stroke and patent foramen ovale: an observational study. Front Neurol 2018; 9: 996.
32. Katsanos AH, Psaltopoulou T, Sergentanis TN, Frogoudaki A, Vrettou AR, Ikonomidis I, et al. Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischaemia: A systematic review and diagnostic test accuracy meta-analysis. Ann Neurol 2016; 79(4): 625–35.
33. Wessler BS, Kent DM, Thaler DE, Ruthazer R, Lutz JS, Serena J. The RoPE Score and Right-to-Left Shunt Severity by Transcranial Doppler in the CODICIA Study. Cerebrovasc Dis 2015; 40(1-2): 52–8.
34. Kasner SE, Lattanzi S, Fonseca AC, Elgendy AY. Uncertainties and controversies in the management of ischaemic stroke and transient ischaemic attack patients with patent foramen ovale. Stroke 2021; 52(12): e806–e19.
35. Lee M, Oh JH. Echocardiographic diagnosis of right-to-left shunt using transoesophageal and transthoracic echocardiography. Open Heart 2020; 7(2).
36. Liu F, Kong Q, Zhang X, Li Y, Liang S, Han S, et al. Comparative analysis of the diagnostic value of several methods for the diagnosis of patent foramen ovale. Echocardiography 2021; 38(5): 790–7.
37. Park S, Oh JK, Song JK, Kwon B, Kim BJ, Kim JS, et al. Transcranial doppler as a screening tool for high-risk patent foramen ovale in cryptogenic stroke. J Neuroimaging 2021; 31(1): 165–70.
38. Mojadidi MK, Bogush N, Caceres JD, Msaouel P, Tobis JM. Diagnostic accuracy of transesophageal echocardiogram for the detection of patent foramen ovale: a meta-analysis. Echocardiography 2014; 31(6): 752–8.
39. Mojadidi MK, Roberts SC, Winoker JS, Romero J, Goodman-Meza D, Gevorgyan R, et al. Accuracy of transcranial Doppler for the diagnosis of intracardiac right-to-left shunt: a bivariate metaanalysis of prospective studies. JACC Cardiovasc Imaging 2014; 7(3): 236–50.
40. Mojadidi MK, Winoker JS, Roberts SC, Msaouel P, Zaman MO, Gevorgyan R, et al. Accuracy of conventional transthoracic echocardiography for the diagnosis of intracardiac right-to-left shunt: a meta-analysis of prospective studies. Echocardiography 2014; 31(9): 1036–48.
41. Radico F, Foglietta M, Di Fulvio M, Appignani M, Rossi S, Angelis MV, et al. The 'dreaded PFO': anatomical and functional features of high risk for stroke. Eur Heart J Suppl 2021; 23(Suppl E): E189–E93.
42. Kolte D, Palacios IF. Patent foramen ovale closure for secondary prevention of cryptogenic stroke. Expert Rev Cardiovasc Ther 2021; 19(3): 211–20.
43. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013; 81(7): 619–25.
44. Kuijpers T, Spencer FA, Siemieniuk RAC, Vandvik PO, Otto CM, Lytvyn L, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ 2018; 362: k2515.
45. Elzanaty AM, Patel N, Sabbagh E, Eltahawy EA. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements. Curr Med Res Opin 2021; 37(3): 377–84.
46. Yaghi S, Raz E, Yang D, Cutting S, Mac Grory B, Elkind MS, et al. Lacunar stroke: mechanisms and therapeutic implications. J Neurol Neurosurg Psychiatry 2021:jnnp-2021-326308. doi: 10.1136/jnnp-2021-326308.
47. Turc G, Lee JY, Brochet E, Kim JS, Song JK, Mas JL, et al. Atrial septal aneurysm, shunt size, and recurrent stroke risk in patients with patent foramen ovale. J Am Coll Cardiol 2020; 75(18): 2312–20.
48. Mac Grory B, Ohman EM, Feng W, Xian Y, Yaghi S, Kamel H, et al. Advances in the management of cardioembolic stroke associated with patent foramen ovale. BMJ 2022; 376: e063161.
49. Kent DM, Saver JL, Kasner SE, Nelson J, Carroll JD, Chatellier G, et al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomised trials of device closure of patent foramen ovale after stroke. JAMA 2021; 326(22): 2277–86.
50. Thaler A, Kvernland A, Kelly S, Song C, Aparicio HJ, Mac Grory B, et al. Stroke prevention in patients with patent foramen ovale. Curr Cardiol Rep 2021; 23(12): 183.
51. Mazzucco S, Li L, Rothwell MP. Prognosis of cryptogenic stroke with patent foramen ovale at older ages and implications for trials: a population-based study and systematic review. JAMA Neurol 2020; 77(10): 1279–87.
52. Merkler AE, Gialdini G, Yaghi S, Okin PM, Iadecola C, Navi BB, et al. Safety outcomes after percutaneous transcatheter closure of patent foramen ovale. Stroke 2017; 48(11): 3073–7.
53. Poli S, Siebert E, Mbroh J, Poli K, Krumbholz M, Mengel A, et al. Closure or medical therapy of patent foramen ovale in cryptogenic stroke: prospective case series. Neurol Res Pract 2021; 3(1): 16.
54. Yuan K, Kasner SE. Patent foramen ovale and cryptogenic stroke: diagnosis and updates in secondary stroke prevention. Stroke Vasc Neurol 2018; 3(2): 84–91.
55. Mas JL, Derex L, Guerin P, Guillon B, Habib G, Juliard JM, et al. Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology. Arch Cardiovasc Dis 2019; 112(8-9): 532–42.
56. Chen JZ, Thijs VN. Atrial fibrillation following patent foramen ovale closure: systematic review and meta-analysis of observational studies and clinical trials. Stroke 2021; 52(5): 1653–61.
57. Shah AH, Osten M, Benson L, Alnasser S, Bach Y, Vishwanath R, et al. Incidence and outcomes of positive bubble contrast study results after transcatheter closure of a patent foramen ovale. JACC Cardiovasc Interv 2018; 11(11): 1095–104.
58. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380(20): 1906–17.
59. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378(23): 2191–201.
60. Huber C, Wachter R, Pelz J, Michalski D. Current challenges and future directions in handling stroke patients with patent foramen ovale-a brief review. Front Neurol 2022; 13: 855656.